107 related articles for article (PubMed ID: 8740972)
21. A fusion protein of IL-8 and a Fab antibody fragments binds to IL-8 receptors and induces neutrophil activation.
Holzer W; Petersen F; Strittmatter W; Matzku S; von Hoegen I
Cytokine; 1996 Mar; 8(3):214-21. PubMed ID: 8833036
[TBL] [Abstract][Full Text] [Related]
22. A novel leukocyte chemotactic and activating cytokine, interleukin-8 (IL-8).
Mukaida N; Harada A; Matsushima K
Cancer Treat Res; 1995; 80():261-86. PubMed ID: 8821581
[No Abstract] [Full Text] [Related]
23. Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis.
Quan JM; Martin TR; Rosenberg GB; Foster DC; Whitmore T; Goodman RB
Biochem Biophys Res Commun; 1996 Feb; 219(2):405-11. PubMed ID: 8605000
[TBL] [Abstract][Full Text] [Related]
24. Regulation of interleukin-8 receptor expression in human polymorphonuclear neutrophils.
Manna SK; Bhattacharya C; Gupta SK; Samanta AK
Mol Immunol; 1995 Aug; 32(12):883-93. PubMed ID: 7565815
[TBL] [Abstract][Full Text] [Related]
25. An anti-interleukin 8 monoclonal antibody that interferes with the binding of interleukin 8 to cellular receptors and the activation of human blood neutrophils.
Kurdowska A; Miller EJ; Cohen AB
Hybridoma; 1995 Jun; 14(3):225-33. PubMed ID: 7590784
[TBL] [Abstract][Full Text] [Related]
26. Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2.
Li F; Gordon JR
Biochem Biophys Res Commun; 2001 Aug; 286(3):595-600. PubMed ID: 11511101
[TBL] [Abstract][Full Text] [Related]
27. Dansyl cadaverine regulates ligand induced endocytosis of interleukin-8 receptor in human polymorphonuclear neutrophils.
Ray E; Samanta AK
FEBS Lett; 1996 Jan; 378(3):235-9. PubMed ID: 8557108
[TBL] [Abstract][Full Text] [Related]
28. Synthetic hexa- and heptapeptides that inhibit IL-8 from binding to and activating human blood neutrophils.
Hayashi S; Kurdowska A; Miller EJ; Albright ME; Girten BE; Cohen AB
J Immunol; 1995 Jan; 154(2):814-24. PubMed ID: 7814885
[TBL] [Abstract][Full Text] [Related]
29. Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin.
Ramdin L; Perks B; Sheron N; Shute JK
Clin Exp Allergy; 1998 May; 28(5):616-24. PubMed ID: 9645599
[TBL] [Abstract][Full Text] [Related]
30. A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptor.
Baly DL; Horuk R; Yansura DG; Simmons LC; Fairbrother WJ; Kotts C; Wirth CM; Gillece-Castro BL; Toy K; Hesselgesser J; Allison DE
J Immunol; 1998 Nov; 161(9):4944-9. PubMed ID: 9794430
[TBL] [Abstract][Full Text] [Related]
31. Multiple sites on IL-8 responsible for binding to alpha and beta IL-8 receptors.
Schraufstätter IU; Barritt DS; Ma M; Oades ZG; Cochrane CG
J Immunol; 1993 Dec; 151(11):6418-28. PubMed ID: 8245475
[TBL] [Abstract][Full Text] [Related]
32. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties.
Wuyts A; Van Osselaer N; Haelens A; Samson I; Herdewijn P; Ben-Baruch A; Oppenheim JJ; Proost P; Van Damme J
Biochemistry; 1997 Mar; 36(9):2716-23. PubMed ID: 9054580
[TBL] [Abstract][Full Text] [Related]
33. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8.
Walz A; Burgener R; Car B; Baggiolini M; Kunkel SL; Strieter RM
J Exp Med; 1991 Dec; 174(6):1355-62. PubMed ID: 1744577
[TBL] [Abstract][Full Text] [Related]
34. Identification of G-protein binding sites of the human interleukin-8 receptors by functional mapping of the intracellular loops.
Damaj BB; McColl SR; Neote K; Songqing N; Ogborn KT; Hébert CA; Naccache PH
FASEB J; 1996 Oct; 10(12):1426-34. PubMed ID: 8903513
[TBL] [Abstract][Full Text] [Related]
35. Mapping of the extracellular binding regions of the human interleukin-8 type B receptor.
Katancik JA; Sharma A; Radel SJ; De Nardin E
Biochem Biophys Res Commun; 1997 Mar; 232(3):663-8. PubMed ID: 9126332
[TBL] [Abstract][Full Text] [Related]
36. IL-8 and NAP-2 differ in their capacities to bind and chemoattract 293 cells transfected with either IL-8 receptor type A or type B.
Ben-Baruch A; Bengali K; Tani K; Xu L; Oppenheim JJ; Wang JM
Cytokine; 1997 Jan; 9(1):37-45. PubMed ID: 9067094
[TBL] [Abstract][Full Text] [Related]
37. Structural change and receptor binding in a chemokine mutant with a rearranged disulfide: X-ray structure of E38C/C50AIL-8 at 2 A resolution.
Eigenbrot C; Lowman HB; Chee L; Artis DR
Proteins; 1997 Apr; 27(4):556-66. PubMed ID: 9141135
[TBL] [Abstract][Full Text] [Related]
38. Use of immobilized synthetic peptides for the identification of contact sites between human interleukin-6 and its receptor.
Weiergräber O; Schneider-Mergener J; Grötzinger J; Wollmer A; Küster A; Exner M; Heinrich PC
FEBS Lett; 1996 Jan; 379(2):122-6. PubMed ID: 8635575
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for differential binding of the interleukin-8 monomer and dimer to the CXCR1 N-domain: role of coupled interactions and dynamics.
Ravindran A; Joseph PR; Rajarathnam K
Biochemistry; 2009 Sep; 48(37):8795-805. PubMed ID: 19681642
[TBL] [Abstract][Full Text] [Related]
40. Chemoattractant cross-desensitization of the human neutrophil IL-8 receptor involves receptor internalization and differential receptor subtype regulation.
Sabroe I; Williams TJ; Hébert CA; Collins PD
J Immunol; 1997 Feb; 158(3):1361-9. PubMed ID: 9013980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
